表紙
市場調査レポート

世界の細胞診とヒトパピローマウイルス(HPV)検査市場

Cytology and HPV Testing World Markets

発行 TriMark Publications 商品コード 191460
出版日 ページ情報 英文 128 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
世界の細胞診とヒトパピローマウイルス(HPV)検査市場 Cytology and HPV Testing World Markets
出版日: 2012年11月01日 ページ情報: 英文 128 Pages
概要

当レポートでは、病院、クリニック、ラボ、研究機関で病気の診断やモニタリング用の細胞やプロテインを検出するのに用いられる測定装置、試薬などを分析し、ヒトパピローマウイルス(HPV)検査をはじめとした細胞診および関連分子診断検査の動向などについて、概略下記の内容でお届けいたします。

第1章 概要

第2章 癌の生物学と診断業界のイントロダクション

  • バイオテクノロジーおよび診断業界の促進因子
  • 腫瘍マーカーの見通し
  • 癌市場

第3章 子宮頸部細胞診の概要

  • 背景情報
  • 子宮頸がん
  • 市場機会
  • 子宮頸がんの細胞診に基づいたスクリーニング
  • 子宮頸がんスクリーニングの新ガイドライン
  • パップスメア(子宮頸部細胞診)市場における新スクリーニングガイドラインの影響

第4章 細胞診市場の構造

  • 主要企業
  • BD-TriPathの子宮頸がん製品
  • Hologicの子宮頸がんスクリーニング製品
  • CytoCore, Inc製品とサービス
  • Ventana (Roche)の子宮頸がんスクリーニング

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: TMRCHPV12-1101

Abstract

Description

image1

Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal cells. If the spread is not controlled, it can result in death. Cancer is caused by both external (chemicals, radiation and viruses) and internal (hormones, immune conditions and inherited mutations) factors. Causal factors may act together or in sequence to initiate or promote carcinogenesis. Ten or more years often pass between exposures or mutations and detectable cancer. Cancer is treated by surgery, radiation, chemotherapy, hormones and immunotherapy. The purpose of this TriMark Publications report is to describe the specific segment of the diagnostic market aimed at analysis cytology (the examination of cells using optical microscopy methods) specimens derived from the human female reproductive tract. It examines the measurement devices and their reagents and supplies used in hospitals, clinics, commercial laboratories and research institutions to detect cells and proteins for the diagnosis and monitoring of disease. The study describes the analytical methods used to separate, isolate, characterize and quantitate cells, DNA and proteins complex in biological systems related to the diagnosis and treatment of disease of the female reproductive tract, such as the cervix and vagina. The emphasis is on those companies and products that are actively developing and marketing laboratory instrumentation, reagents and supplies for performing cytology and related molecular diagnostic tests, such as human papillomavirus (HPV) and other inflammatory and sexually-transmitted diseases.

Table of Contents

1. Overview 6

  • 1.1 Statement of Report
  • 1.2 About this Report
  • 1.3 Scope of the Report
  • 1.4 Objectives
  • 1.5 Methodology

2. Introduction to Cancer Biology and the Diagnostic Industry

  • 2.1 Cancer
    • 2.1.1 The Disease
    • 2.1.2 Metastasis
    • 2.1.3 Demographics and Statistics of Cancer
  • 2.2 The Drivers of the Biotech and Diagnostics Industry
    • 2.2.1 Top Ten Biotech Corporations Based on Innovation as Determined by FastCompany Magazine
    • 2.2.2 Technological Innovation
    • 2.2.3 Government Funding
    • 2.2.4 Pharmaceutical Development
  • 2.3 Outlook for Tumor Markers
  • 2.4 The Cancer Market

3. Cervical Cytology Testing Overview

  • 3.1 Sector Background
  • 3.2 Cervical Cancer
  • 3.3 Market Opportunity
  • 3.4 Cytology-Based Screening for Cervical Cancer
    • 3.4.1 Accuracy and Limitations of Pap Smears
    • 3.4.2 Liquid-Based Pap Smear Technologies and Automation
  • 3.5 New Guidelines for Cervical Cancer Screenings
  • 3.6 Impact of New Screening Guidelines on the Pap Smear Market

4. Cytology Market Structure

  • 4.1 Key Players
    • 4.1.1 BD Diagnostics (Acquired TriPath Imaging)
    • 4.1.2 Hologic, Inc. (Acquired Cytyc)
    • 4.1.3 CytoCore, Inc. (Formerly Known as Molecular Diagnostics, Inc.)
    • 4.1.4 Ventana Medical Systems, Inc. (A Member of the Roche Group)
    • 4.1.5 Pap Smear Market Share
  • 4.2 BD-TriPath Cervical Cytology Product Line
    • 4.2.1 BD SurePath Pap Test
    • 4.2.2 BD Cell Enrichment Process
    • 4.2.3 BD PrepStain Slide Processor
    • 4.2.4 BD FocalPoint Slide Profiler
    • 4.2.5 BD FocalPoint GS Imaging System
    • 4.2.6 Manufacturing of BD-TriPath Cytology Products
    • 4.2.7 Molecular Oncology
  • 4.3 Hologic Cervical Cancer Screening Products
    • 4.3.1 The ThinPrep System
  • 4.4 CytoCore, Inc. Products
    • 4.4.1 SoftPAP Cervical Cell Collector
    • 4.4.2 CytoCore Products in Development
  • 4.5 Ventana (Roche) Cervical Cancer Screening
Back to Top